Microcirculatory Changes During Magnesium Sulphate Infusion in Sepsis
Overview
During infections (sepsis) bloodflow in small vessels (microcirculation) becomes disturbed. Restoration of bloodpressure and cardiac performance may not be sufficient to correct these alterations. Magnesium is a potent vasodilator which may be used to open up the small vessels, in order to reduce organ failure.
Full Title of Study: “Microcirculatory Changes During Open Label Magnesium Sulphate Infusion in Severe Sepsis and Septic Shock”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: August 2010
Detailed Description
In a single-center open label study we evaluated the effects of magnesium sulphate (MgS) infusion on the sublingual microcirculation perfusion in fluid resuscitated patients with severe sepsis and septic shock within the first 48 hours after ICU admission. Directly prior to and after 1 hour of magnesium sulphate (MgS) infusion (2 gram) systemic hemodynamic variables, sublingual SDF images and standard laboratory tests, were obtained.
Interventions
- Drug: Magnesium Sulfate
- 2 gram in 1 hour
Arms, Groups and Cohorts
- severe sepsis and septic shock
Clinical Trial Outcome Measures
Primary Measures
- microvascular flow index
- Time Frame: 1 hour
- Directly prior to and after 1 hour of magnesium sulphate (MgS) infusion (2 gram) systemic hemodynamic variables, sublingual SDF images and standard laboratory tests, were obtained.
Participating in This Clinical Trial
Inclusion Criteria
- severe sepsis and septic shock Exclusion Criteria:
- pregnancy – oral bleeding – age < 18 years – liver cirrhosis – acute arrhythmias – advanced malignancy or a mean arterial pressure (MAP) < 65 mmHg refractory to vasopressors
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Medical Centre Leeuwarden
- Collaborator
- Lithuanian University of Health Sciences
- Provider of Information About this Clinical Study
- Andrius Pranskunas, Lithuanian University of Health Sciences
- Overall Official(s)
- A Pranskunas, MD, Principal Investigator, Lithuanian university of sciences
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.